SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
SCYNEXIS, Inc. (NASDAQ: SCYX) announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 in Los Angeles, CA from October 16-19, 2024. The company will present two sessions:
1. An oral presentation titled 'Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections' on October 17.
2. A poster presentation titled 'SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential' on October 18.
Both presentations will be delivered by David A. Angulo, M.D., President and CEO of SCYNEXIS.
SCYNEXIS, Inc. (NASDAQ: SCYX) ha annunciato prossimi interventi sui dati di efficacia preclinica e farmacocinetica del suo candidato fungico di seconda generazione SCY-247 durante IDWeek 2024 a Los Angeles, CA, dal 16 al 19 ottobre 2024. L'azienda presenterà due sessioni:
1. Una presentazione orale intitolata 'Efficacia di SCY-247, un antifungino triterpenoide di seconda generazione, in tre modelli murini di infezioni fungine invasive' il 17 ottobre.
2. Una presentazione poster intitolata 'SCY-247: un antifungino triterpenoide IV/Orale di seconda generazione con ampia distribuzione nei tessuti e farmacocinetica, e basso potenziale di interazione farmacologica' il 18 ottobre.
Entrambe le presentazioni saranno tenute da David A. Angulo, M.D., Presidente e CEO di SCYNEXIS.
SCYNEXIS, Inc. (NASDAQ: SCYX) anunció próximas presentaciones de datos de eficacia preclínica y farmacocinética sobre su candidato antifúngico de segunda generación SCY-247 en IDWeek 2024 en Los Ángeles, CA, del 16 al 19 de octubre de 2024. La empresa presentará dos sesiones:
1. Una presentación oral titulada 'Eficacia de SCY-247, un antifúngico triterpenoide de segunda generación, en tres modelos murinos de infecciones fúngicas invasivas' el 17 de octubre.
2. Una presentación de póster titulada 'SCY-247: un antifúngico triterpenoide IV/Oral de segunda generación con amplia distribución en tejidos y farmacocinética, y bajo potencial de interacción entre medicamentos' el 18 de octubre.
Ambas presentaciones serán impartidas por David A. Angulo, M.D., Presidente y CEO de SCYNEXIS.
SCYNEXIS, Inc. (NASDAQ: SCYX)는 2024년 10월 16일부터 19일까지 캘리포니아주 로스앤젤레스에서 열리는 IDWeek 2024에서 2세대 항진균 후보 SCY-247에 대한 전임상 효능 및 약리학적 데이터 발표를 예고했습니다. 이 회사는 두 가지 세션을 진행할 예정입니다:
1. '3가지 murine 모델에서의 SCY-247의 효능, 2세대 트리터페노이드 항진균제'라는 제목의 구두 발표가 10월 17일에 진행됩니다.
2. 'SCY-247: 광범위한 조직 분포 및 약리학, 낮은 약물-약물 상호작용 잠재성을 가진 2세대 IV/경구 트리터페노이드 항진균제'라는 제목의 포스터 발표가 10월 18일에 진행됩니다.
두 발표 모두 SCYNEXIS의 사장 겸 CEO인 David A. Angulo, M.D.가 진행합니다.
SCYNEXIS, Inc. (NASDAQ: SCYX) a annoncé des présentations à venir sur l'efficacité préclinique et les données pharmacocinétiques de son candidat antifongique de deuxième génération SCY-247 lors de IDWeek 2024 à Los Angeles, CA, du 16 au 19 octobre 2024. L'entreprise présentera deux sessions :
1. Une présentation orale intitulée 'Efficacité de SCY-247, un antifongique triterpénoïde de deuxième génération, dans trois modèles murins d'infections fongiques invasives' le 17 octobre.
2. Une présentation par affiche intitulée 'SCY-247 : un antifongique triterpénoïde IV/oral de deuxième génération avec une large distribution dans les tissus et une pharmacocinétique, ainsi qu'un faible potentiel d'interaction médicamenteuse' le 18 octobre.
Les deux présentations seront réalisées par David A. Angulo, M.D., Président et PDG de SCYNEXIS.
SCYNEXIS, Inc. (NASDAQ: SCYX) gab bekannt, dass sie auf der IDWeek 2024, die vom 16. bis 19. Oktober 2024 in Los Angeles, CA, stattfindet, Präsentationen über präklinische Wirksamkeits- und Pharmakokinetikdaten ihres zweite Generation fungizide Kandidaten SCY-247 halten wird. Das Unternehmen wird zwei Sitzungen präsentieren:
1. Eine mündliche Präsentation mit dem Titel 'Wirksamkeit von SCY-247, einem zweitgenerationen Triterpenoid-Antimykotikum, in drei murinen Modellen invasiver Pilzinfektionen' am 17. Oktober.
2. Eine Posterpräsentation mit dem Titel 'SCY-247: Ein zweitgenerationen IV/oral Triterpenoid-Antimykotikum mit umfangreicher Gewebeverteilung und Pharmakokinetik sowie geringem Potenzial für Arzneimittelwechselwirkungen' am 18. Oktober.
Beide Präsentationen werden von David A. Angulo, M.D., Präsident und CEO von SCYNEXIS gehalten.
- Presentation of preclinical efficacy data for SCY-247 at a major infectious disease conference
- Development of a second-generation antifungal candidate with potential for both IV and oral administration
- Potential for extensive tissue distribution and low drug-drug interaction of SCY-247
- None.
JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 taking place in Los Angeles, CA from October 16-19, 2024.
Presentation details can be found below:
Oral Presentation:
| Title: | Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections |
| Session: | Mycology Matters: Insights into Fungal Infections |
| Date/Time: | Thursday October 17, 2024 at 10:45 AM PDT |
| Location: | Los Angeles Convention Center, Room 403 B |
| Presenting author: | David A. Angulo, M.D., President and CEO of SCYNEXIS |
Poster Presentation:
| Title: | SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential |
| Session: | New Drug Development |
| Date/Time: | Friday October 18, 2024 at 12:15 – 1:30 PM PDT |
| Location: | Los Angeles Convention Center, Halls JK |
| Presenting author: | David A. Angulo, M.D., President and CEO of SCYNEXIS |
For more information, see the IDWeek website here.
About SCY-247
SCY-247 is a second-generation antifungal compound, from a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids (fungerps), being developed to address the significant threat posed by antimicrobial resistance (AMR) in systemic fungal diseases with high mortality. The triterpenoid class of antifungals represents the first new class of antifungal compounds approved since 2001. These agents combine the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. SCY-247 is in pre-IND development stage and has demonstrated in vitro and in vivo broad-spectrum antifungal activity, including against multidrug resistant fungal pathogens. SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for the IV and oral formulations of SCY-247.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps”. Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com.
Forward-Looking Statements
Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for the IV and oral formulations of SCY-247. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 28, 2024, and form 10-Q for the quarter ending June 30, 2024, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com
FAQ
What is SCYNEXIS presenting at IDWeek 2024 regarding SCY-247?
When and where will SCYNEXIS (SCYX) present the SCY-247 data at IDWeek 2024?
What are the potential advantages of SCYNEXIS's (SCYX) SCY-247 antifungal candidate?
